Avid Bioservices Inc (CDMO)

[JamesGMS]

And the Beat goes on.

Historical Short Volume Data for PPHM
Date Close High Low Volume Short Volume % of Vol Shorted
Dec 14 NA NA NA 144,101 66,516 46.16
Dec 13 NA NA NA 166,511 68,606 41.20
Dec 12 NA NA NA 542,707 263,849 48.62
Dec 11 NA NA NA 125,901 43,534 34.58
Dec 08 NA NA NA 61,504 32,309 52.53
Dec 07 NA NA NA 89,804 43,202 48.11
Dec 06 NA NA NA 46,117 29,049 62.99

Until it just stops - and then Joe's thoughts from earlier today on possible volume at that juncture will likely be on target or even low. We'll see. : )

Interesting post this morning CP.

You may be right on target.

4) As per the above 1 to 3, KITE/GILD and NOVARTIS remain as the ONLY two contenders in this CAR-T+PtdSer scenario. But NOVARTIS's CEO has made a statement on CNBC that the IO companies that remain for acquisition are expensive and that they prefer to WAIT.

That was BEFORE KITE got CAR-T approved and BEFORE GILD acquired KITE and BEFORE MSK Dr. Wolchok's pre-clinical results were available.

The Gilead CEO also made a statement before all that was known, namely, that they were searching for a new cornerstone molecule.

I think they found that with KITE and that PtdSer for them may just be the cement they need to seal that cornerstone to the ground and make it better then other cornerstones.

And GILD is the company that will spare no expense to get there while Novartis is much more conservative.

. . . . . . . . . .

MSKCC is waiting to run an already designed experimental clinical trial on humans for CAR-T+PtdSer-Targeting in a solid cancer (possibly all solid cancers given the 'experimental') and needs a GO (at the time of writing) from PPHM.

PPHM is negotiating final terms with GILD and when finalised GILD/KITE will be the company that will have to give the GO to MSKCC.

Novartis is second runner up and only would have stood a chance if they drop the conservative approaches of acquisition because against GILD they don't stand a chance that way.

JUNO became an outsider by lack of CAR-T approval, only a 10-year agreement will Celgene vs acquisition and by lack of sufficient own pocket depth to compete with the others.

All 3 companies have not meaningfully invested in traditional anti-PD-1, anti-CTLA-4, etc.

CAR-T is their chance to short-circuit that with a better solution.

This is THEIR chance to win a WAR they didn't even participate in.

Good read on GILD - And the massive new construction they've had going on for the past few years is now nearing completion. Lots of new folks to hire.

Best line of the week - if not the month: "Winning a WAR they didn't even participate in"

Have a nice evening.

James